The argument for using imatinib in CML

Autor Claudiani, Simone, Apperley, Jane F.
Vydáno v Hematology Am Soc Hematol Educ Program (2018)

Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations

Autor Claudiani, Simone, Apperley, Jane F., Khan, Afzal, Khorashad, Jamshid, Milojkovic, Dragana
Vydáno v Haematologica (2020)

E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy

Autor Claudiani, Simone, Apperley, Jane F., Gale, Robert Peter, Clark, Richard, Szydlo, Richard, Deplano, Simona, Palanicawandar, Renuka, Khorashad, Jamshid, Foroni, Letizia, Milojkovic, Dragana
Vydáno v Haematologica (2017)

MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia

Autor Claudiani, Simone, Gatenby, Aoife, Szydlo, Richard, Nesr, George, Abulafia, Adi Shacham, Palanicawandar, Renuka, Nteliopoulos, Georgios, Khorashad, Jamshid, Foroni, Letizia, Apperley, Jane F., Milojkovic, Dragana
Vydáno v Haematologica (2019)

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors

Autor Nteliopoulos, Georgios, Bazeos, Alexandra, Claudiani, Simone, Gerrard, Gareth, Curry, Edward, Szydlo, Richard, Alikian, Mary, Foong, Hui En, Nikolakopoulou, Zacharoula, Loaiza, Sandra, Khorashad, Jamshid S., Milojkovic, Dragana, Perrotti, Danilo, Gale, Robert Peter, Foroni, Letizia, Apperley, Jane F.
Vydáno v Haematologica (2019)